iPS cell derived macrophage therapy against familial amyloid polyneuropathy
| Project/Area Number |
26860673
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Neurology
|
|---|
| Research Institution | Kumamoto University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2014-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2015: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Keywords | iPS cell / FAP / macrophage / neurology / 家族性アミロイドポリニューロパチー / iPS 細胞 / アミロイド / マクロファージ |
|---|
| Outline of Final Research Achievements |
Cardiac autopsy tissue from FAP patients has a reduction in M2 macrophages which is considered to have strong anti-inflammatory effect. In contrast with the FAP patient serum, which recognizes the increase of inflammatory cytokines IL-6, chronic inflammation occurs in FAP, may be causing a variety of organ damage. In this research, iPS cells derived macrophages showed a strong phagocytosis against the wild type and mutant forms of transthyretin (TTR). Inducing the differentiation M2 phenotype macrophages from iPS cells, maybe a new therapeutic strategy treating FAP patient.
|
Report
(3 results)
Research Products
(1 results)
